Currently out of the existing stock ratings of Derik De Bruin, 20 are a SELL (16.26%), 50 are a HOLD (40.65%), 53 are a BUY (43.09%).

Derik De Bruin

Work Performance Price Targets & Ratings Chart

Analyst Derik De Bruin, currently employed at BAML, carries an average stock price target met ratio of 77.6% that have a potential upside of 17.21% achieved within 160 days.

Derik De Bruin’s has documented 255 price targets and ratings displayed on 30 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on A, Agilent Technologies at 13-Dec-2024.

Wall Street Analyst Derik De Bruin

Analyst best performing recommendations are on TLIS (TALIS BIOMEDICAL CORP).
The best stock recommendation documented was for TLIS (TALIS BIOMEDICAL CORP) at 3/16/2022. The price target of $22.5 was fulfilled within 2 days with a profit of $3 (15.38%) receiving and performance score of 76.92.

Average potential price target upside

of $80.06 (9.69%) on MTD (METTLER-TOLEDO INTERNATIONAL).
of $38.33 (27.12%) on LH (LABORATORY OF AMERICA HOLDINGS).
of $34.86 (14.3%) on IDXX (IDEXX LABORATORIES).

ILMN Illumina A Agilent Technologies AVTR Avantor BRKR Bruker DGX Quest Diagnostics DNA Ginkgo Bioworks Holdings GH Guardant Health HOLX Hologic IQV IQVIA Holdings LH Laboratory of America Holdings MTD Mettler-Toledo International MYGN Myriad Genetics PKI PerkinElmer QGEN Qiagen NV SEER Seer TXG 10X Genomics STVN Stevanato Group SpA TX Ternium SA ADR CTLT Catalent DHR Danaher EXAS EXACT Sciences IDXX IDEXX Laboratories PSNL Personalis TLIS Talis Biomedical Corp WAT Waters WST West Pharmaceutical Services ICLR ICON PLC CRL Charles River Laboratories NEO NeoGenomics ZTS Zoetis

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Tejas Savant (MORGAN STANLEY)